Akili Interactive, a digital medicine company, announced this week its plans to move to a non-prescription business model, and restructure its workforce in the process.
The company holds the only FDA-prescription video game treatment, EndeavorRx, approved for patients aged 8 to 12 yers old with primarily inattentive or combined-type ADHD.
In studies, adolescents using EndeavorRx saw substantial reductions in ADHD symptoms, with 27% achieving a significant improvement, as well as improvements to their attention. Nearly 66% of adolescents met the prespecified definition of clinical response in attention comparison score assessments.
As a part of their restructuring, the company will also be letting go of 40% of its staff, which includes the elimination of their field sales force and market access teams. With the savings, the company plans to drive consumer awareness and business expansion.
